Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey

Acta Haematologica

Volumn 102, Issue 1, 1999, Pages 17-21

  Aydinok, Yesim ^a   Nisli, G ^a   Kavakli, K ^a   Coker, C ^a   Kantar, M ^a   Cetingul N ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Deferiprone; Desferrioxamine; Ferritin; Fibrosis; Hepatic iron; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER INJURY; LIVER LEVEL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR; TURKEY (REPUBLIC); URINE LEVEL;

ADOLESCENT; BETA-THALASSEMIA; CHELATING AGENTS; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; PYRIDONES; STUDENTS; TURKEY;

EID: 0032820582     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040962     Document Type: Article

References (17)

1. Konthoghiorges GJ, Hoffbrand AV: Iron chelation therapy; in Current Therapy in Hematology-Oncology, ed 4. Philadelphia, Decker, 1992, pp 144-148.
2. Hoffbrand AV, Wonke B: Iron chclation therapy. J Intern Med 1997;242(suppl 740):37-41.
3. Olivieri NF: Long-term therapy with deferiprone. Acta Haematol 1996;95:37-48.
4. Nixon DE, Moyer TP, Johnson P, McCall JT, Ness AB, Fjerstad WH, Wehde MB: Routine measurement of calcium, magnesium, copper, zinc and iron in urine and serum by inductively coupled plasma emission spectroscopy. Clin Chem 1986;32:1660-1665.
5. Robbins DA: Metals in blood or tissue; in Kreip TJ, Crable JV (eds): Methods for Biological Monitoring. New York, American Public Health Association, 1988, chap 118, pp 223-227.
6. Olivieri NF, Brittenham GM: Iron chelating therapy and the treatment of thalassemia. Blood 1977;89:739-761.
7. Brittenham GM, Griffith PM, Nienhuis AW: Efficacy of desferrioxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331: 567-573.
8. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991;13:431-435.
9. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578.
10. 1) in thalassemia major. Blood 1992;80:592-599.
11. 1, and oral iron chelator, in transfusion-dependent thalassemia: Indian trial. Br J Haematol 1992;82:460-466.
12. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF: Arthropathy in thalassemia patients receiving deferiprone. Lancet 1994;343:1471-1472.
13. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron R, McClelland RA, Liu PP, Templeton DM, Koren G: Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-922.
14. Hoffbrand AV, Al-Refaie F, Davis B, Siritanatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91/1:295-300.
15. Wonke B, Wright C, Hoffbrand AV: Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
16. 1) and deferoxamine (DFO) in thalassemia major. Blood 1996;88:310a.
17. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA, Phil D: Long-term safety and effectiveness of iron-chelation therapy with deferiprone thalassemia major. N Engl J Med 1998;339:417-423.